Calendar of CURE/Yale BioHaven seminars for Fall 2010 now available. more
9/14
8:45 am - 6:00 pm
Ubifrance, the French Agency for international business development, cordially invites CURE members to this year's second French Biotech Tour, which aims to connect French and American Biotech companies specialized in neuroscience, inflammation, and auto-immune diseases. Philadelphia, PA. more
9/16
6:00 pm - 7:30 pm
CURE/Yale BioHaven presents Al Mann: 'Creating a successful medical device enterprise.' Hope Auditorium, Yale University, 315 Cedar Street, New Haven. more
10/5
Deadline for nominations for the Lemelson-MIT prize, awarded to an outstanding mid-career inventor who has developed a patented product or process of significant value to society. more
10/14
4:00 pm - 7:00 pm
Hartford Hospital Research Symposium. 'Personalized Medicine and Genomics: The Future is Now.' RSVP by 10/1 to 860.545.5620. Heublein Hall, Education & Resource Center, Hartford Hospital, Hudson Street, Hartford. more
10/27
4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Cobalt Therapeutics. Anlyan Center, Yale University, 300 Cedar Street, New Haven. more
11/18
4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Biodel Inc. Anlyan Center, Yale University, 300 Cedar Street, New Haven. more
12/7
5:30 pm - 7:30 pm
CURE Holiday Party. Café George, 300 George Street, New Haven. Watch for details.


Genomas, Inc.
 67 Jefferson Street
Hartford, CT 06106

Phone: 860 545 4574
Fax: 860 545 4575
Website: http://genomas.net/

Contact(s)
admin@genomas.net
Gualberto Rua?o, President & CEO

General Information
Genomas? is a biomedical company advancing personalized health with revolutionary PhyzioTypeTM systems for DNA-guided diagnosis and prevention of serious side effects induced by cardiovascular, psychiatric, and diabetic medications. The products are being developed in partnership with three leading CT medical institutions, Hartford Hospital, The Institute of Living and The Hospital of Central Connecticut.

PhyzioTypeTM medical management systems will change the current course of treatment. They provide physicians the unprecedented capability to prevent serious side effects based on the patient?s DNA. By comparing side effect risks of drugs in a therapeutic class for each patient and by forewarning doctors of adverse responses that will complicate treatment, PhyzioTypeTM systems eliminate trial and error with DNA- guided medicine. A PhyzioTypeTM system has 3 proprietary components: an ensemble of inherited, stable DNA markers from several genes, a biostatistical algorithm validated in clinical studies for ascertaining the clinical significance of a patient?s DNA marker configuration, and a graphical portal for doctors to select drugs based on an individual?s risk of developing side effects.

Back

Designed by BlausenLisi
Copyright © 2006 Connecticut United for Research Excellence, Inc.